Terms: = Uterine cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
96 results:
1. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
2. Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.
Peng C; Li X; Tang W; Zhu W; Yan P; Chen J; Zhang X; Guo Q; Wu Q; Wang Q; Liu N; Ma A; Lu Y; Lv P; Liu J; Xie P
Int Immunopharmacol; 2024 Mar; 129():111578. PubMed ID: 38330795
[TBL] [Abstract] [Full Text] [Related]
3. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance and immunological role of HPRT1 in human cancers.
Lu Y; Chen R; Zhang H; Sun X; Li X; Yang M; Zhang X
Biomol Biomed; 2024 Mar; 24(2):262-291. PubMed ID: 38159260
[TBL] [Abstract] [Full Text] [Related]
5. PD-L1 and pd-1 Expression in Early Stage uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
6. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
[TBL] [Abstract] [Full Text] [Related]
7. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
8. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
Zong Y; Chang Y; Huang K; Liu J; Zhao Y
Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
[TBL] [Abstract] [Full Text] [Related]
9. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
[TBL] [Abstract] [Full Text] [Related]
10. The effects of 5-aminolevulinic acid photodynamic therapy on the local immune response of women with cervical intraepithelial neoplasia grade 2.
Wu A; Niu J; Hong Z; Gu L; Huang Y; Qiu L
Front Immunol; 2023; 14():1211114. PubMed ID: 37928525
[TBL] [Abstract] [Full Text] [Related]
11. The inflammatory response-related robust machine learning signature in endometrial cancer: Based on multi-cohort studies.
Zhou C; Xiang P; Xu X; Yue C; Gao K
J Gene Med; 2024 Jan; 26(1):e3603. PubMed ID: 37845174
[TBL] [Abstract] [Full Text] [Related]
12. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical cancer.
Chen X; Hao Y; Liu Y; Zhong S; You Y; Ao K; Chong T; Luo X; Yin M; Ye M; He H; Lu A; Chen J; Li X; Zhang J; Guo X
Adv Sci (Weinh); 2023 Nov; 10(32):e2302705. PubMed ID: 37818745
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer.
Li J; Wan C; Li X; Quan C; Li X; Wu X
J Transl Med; 2023 Sep; 21(1):647. PubMed ID: 37735483
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of pd-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract] [Full Text] [Related]
15. Expression and clinical significance of pd-1 in UCEC and its Impact on tumor.
Xing F; Yang Y; Zheng W
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):168-173. PubMed ID: 37571885
[TBL] [Abstract] [Full Text] [Related]
16. Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances.
Chao A; Wu RC; Lin CY; Chang TC; Lai CH
Biomed J; 2023 Oct; 46(5):100633. PubMed ID: 37467967
[TBL] [Abstract] [Full Text] [Related]
17. Landscape of PCOS co-expression gene and its role in predicting prognosis and assisting immunotherapy in endometrial cancer.
Zhang Y; Hu Y; Yu J; Xie X; Jiang F; Wu C
J Ovarian Res; 2023 Jul; 16(1):129. PubMed ID: 37393293
[TBL] [Abstract] [Full Text] [Related]
18. Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.
Song S; Gu H; Li J; Yang P; Qi X; Liu J; Zhou J; Li Y; Shu P
Sci Rep; 2023 Jun; 13(1):9255. PubMed ID: 37286702
[TBL] [Abstract] [Full Text] [Related]
19. Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma.
Gao J; Fan R; Chen D; Hou J; Chen H; Lu M
Diagn Pathol; 2023 May; 18(1):62. PubMed ID: 37194064
[TBL] [Abstract] [Full Text] [Related]
20. Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.
Zuo Y; Xiao H; Lv D; Huang M; Wang L; Liu J; Zhang K; Shen J; Wang Z; Wu Q; Xu Y
J Med Virol; 2023 Apr; 95(4):e28717. PubMed ID: 37184049
[TBL] [Abstract] [Full Text] [Related]
[Next]
